Harrow Showcases Ophthalmic Portfolio with 15 Scientific Presentations at AAOpt and AAO
Event summary
- Harrow will present 15 scientific abstracts at AAOpt (Sep 30–Oct 3) and AAO (Oct 9–12) 2026, covering dry eye disease, vernal keratoconjunctivitis, and other ophthalmic conditions.
- 13 presentations at AAOpt and 2 at AAO will feature Phase 3 trial results, long-term safety data, and comparative studies.
- Featured products include VEVYE®, VERKAZIA®, FLAREX®, and BYQLOVI®, addressing a range of ophthalmic diseases.
- Presentations span topics such as corneal endothelial health, steroid rescue reduction, and treatment compliance in pediatric patients.
The big picture
Harrow’s extensive scientific presence at AAOpt and AAO underscores its commitment to evidence-based ophthalmic solutions. The focus on dry eye disease and vernal keratoconjunctivitis aligns with growing demand for specialized treatments in these areas. The company’s ability to leverage these presentations for market differentiation will be key in sustaining growth.
What we're watching
- Clinical Validation
- How the breadth of clinical evidence presented will influence physician adoption of Harrow’s products.
- Market Differentiation
- Whether the focus on pediatric and severe ophthalmic conditions can set Harrow apart in a competitive market.
- Regulatory Pathways
- The pace at which Harrow can translate these findings into expanded indications or new product approvals.